Michael Basso
Overview
Explore the profile of Michael Basso including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
231
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Gaasedelen O, Whiteside D, Basso M
Clin Neuropsychol
. 2017 Apr;
31(5):844-856.
PMID: 28391774
Objective: Few studies have evaluated the symptom validity tests (SVTs) within the Personality Assessment Inventory (PAI) in a neuropsychological assessment context. Accordingly, the present study explored the accuracy of PAI...
12.
Norman L, Basso M
Curr Drug Abuse Rev
. 2015 Mar;
8(1):50-71.
PMID: 25751583
Neuropyschological dysfunction, ranging from mild cerebral indicators to dementia has been a consistent part of the medical picture of HIV/AIDS. However, advances in medical supervision, particularly as a result of...
13.
Whiteside D, Kogan J, Wardin L, Phillips D, Franzwa M, Rice L, et al.
J Clin Exp Neuropsychol
. 2015 Feb;
37(2):220-7.
PMID: 25655924
No studies to date have investigated the Boston Naming Test (BNT) as an embedded performance validity test (PVT). This study investigated the classification accuracy of the Boston Naming Test (BNT)...
14.
Basso M, Combs D, Purdie R, Candilis P, Bornstein R
Psychiatry Res
. 2013 Feb;
207(1-2):61-7.
PMID: 23433872
Symptoms of major depressive disorder (MDD) manifest variably across individuals. Accordingly, recent models of the disorder imply that MDD may be characterized according to independent symptom dimensions. In particular, several...
15.
Goverover Y, Basso M, Wood H, Chiaravalloti N, DeLuca J
Mult Scler
. 2011 May;
17(12):1488-97.
PMID: 21586486
Background: Forgetfulness occurs commonly in people with multiple sclerosis (MS), but few treatments alleviate this problem. Objective: This study examined the combined effect of two cognitive rehabilitation strategies to improve...
16.
Ghormley C, Basso M, Candlis P, Combs D
Psychiatry Res
. 2010 Dec;
187(1-2):106-12.
PMID: 21126772
Incapacity to make decisions about medical treatment is associated with neuropsychological impairment in a variety of illnesses. Although cognitive deficits occur often in people with major depressive illness, little research...
17.
Norman L, Basso M, Kumar A, Malow R
Curr Drug Abuse Rev
. 2009 Jul;
2(2):143-56.
PMID: 19630745
Neuropsychological dysfunction, ranging from mild cognitive symptoms to dementia has been a consistent part of the clinical picture of HIV/AIDS. However, advances in clinical management, particularly antiretroviral (ARV) treatment, have...
18.
Wrobel J, Steffan R, Bowen S, Magolda R, Matelan E, Unwalla R, et al.
J Med Chem
. 2008 Nov;
51(22):7161-8.
PMID: 18973288
A series of substituted 2-benzyl-3-aryl-7-trifluoromethylindazoles were prepared as LXR modulators. These compounds were partial agonists in transactivation assays when compared to 1 (T0901317) and were slightly weaker with respect to...
19.
Hu B, Jetter J, Kaufman D, Singhaus R, Bernotas R, Unwalla R, et al.
Bioorg Med Chem
. 2007 Mar;
15(10):3321-33.
PMID: 17391964
A series of phenyl acetic acid based quinolines was prepared as LXR modulators. An SAR study in which the C-3 and C-8 positions of the quinoline core were varied led...
20.
Hu B, Collini M, Unwalla R, Miller C, Singhaus R, Quinet E, et al.
J Med Chem
. 2006 Oct;
49(21):6151-4.
PMID: 17034119
A structure-based approach was used to optimize our new class of quinoline LXR modulators leading to phenyl acetic acid substituted quinolines 15 and 16. Both compounds displayed good binding affinity...